The ANKFY1 Knouckout Jurkat Polyclonal Cells are a polyclonal population of Jurkat T lymphoblastoid cells with CRISPR/Cas9-mediated disruption of the ANKFY1 gene. This loss-of-function model enables the study of ANKFY1, a critical regulator of endocytic trafficking and macropinocytosis. The polyclonal format avoids clonal selection artifacts and allows investigation of ANKFY1-dependent processes in a physiologically relevant T-cell background while retaining the robust proliferation and well-characterized signaling pathways of the parental Jurkat line.
Jurkat cells, derived from a patient with acute T cell leukemia, are a cornerstone model for T cell signaling, apoptosis, and leukemogenesis. Their T lymphoblastoid phenotype and well-defined molecular landscape make them ideal for endocytosis studies, providing an excellent host for dissecting ANKFY1 function. The ANKFY1 knockout in this context allows clean examination of endosomal and macropinocytic pathways without endogenous ANKFY1 interference.
ANKFY1 functions as a Rab5 effector, binding specifically to GTP-bound Rab5 and phosphatidylinositol 3-phosphate (PI3P) on early endosomal membranes. This dual interaction anchors ANKFY1 to nascent endosomes and promotes membrane tubulation and vesiculation required for macropinocytosis and endosomal maturation. Through these activities, ANKFY1 regulates the internalization and subsequent degradation of receptors such as epidermal growth factor receptor (EGFR). It operates downstream of Rab5 activation and PI3K-mediated PI3P production, coupling receptor-mediated endocytosis to the endolysosomal pathway. Other pathway components, including EEA1 and Rab7, are functionally linked to ANKFY1??s role in early-to-late endosome transition.
In the Jurkat T-cell background, disruption of ANKFY1 offers a unique opportunity to explore how endocytic dysregulation impacts hematologic malignancy. While ANKFY1??s role in EGFR trafficking is well established, its loss in a leukemia cell line may reveal alternative cargoes and pathways relevant to T-cell biology, such as those involving cytokine receptors or immune checkpoint molecules. This model is therefore invaluable for studying the intersection of endocytosis, receptor signaling, and oncogenesis in a cell type that is central to both adaptive immunity and leukemia development. It provides a platform to interrogate how defective macropinocytosis and endosomal trafficking contribute to cancer progression.
Typical applications include detailed analysis of endocytosis and macropinocytosis using fluorescent transferrin and dextran uptake assays, quantitative Western blotting for EGFR degradation, and immunofluorescence colocalization with endosomal markers like EEA1 and Rab5. Flow cytometry-based internalization assays and live-cell imaging of vesicle dynamics are also readily performed with this product. Furthermore, the cells are suited for drug delivery and nanoparticle uptake studies, enabling translational research into endolysosomal targeting. For further technical details and customized project support, please contact Ascent Research.
